• About
  • Contact
  • Resources
  • Book Nook
Donate
  • Featured
  • Commentary
  • Science & News
  • Mainstream
    • Mainstream Prevention
    • Mainstream Treatment
    • Vaccines
    • Repurposed Drugs
  • Integrative
    • Integrative Prevention
    • Integrative Treatments
    • Integrative Recovery
      • Long Haul
  • Controversies
    • Ivermectin
  • Blog
    • Michael Lerner’s Blog
    • Guest Authors
MenuClose
  • Featured
  • Commentary
  • Science & News
  • Mainstream Solutions
    • Mainstream Prevention
    • Mainstream Treatment
    • Vaccines
    • Repurposed Drugs
  • Integrative Therapies
    • Integrative Prevention
    • Integrative Treatments
    • Integrative Recovery
      • Long Haul
  • Controversies
    • Ivermectin
  • Blog
    • Guest Authors
    • Michael Lerner’s Blog
  • About
  • Contact
  • Resources
  • Donate

New England Journal of Medicine


Bivalent Covid-19 Vaccines — A Cautionary Tale

Bivalent Covid-19 Vaccines — A Cautionary Tale

by Covid Strategies | Jan 11, 2023 | Featured, Science & News, Vaccines

By Paul A. Offit, M.D. In November 2019, a bat coronavirus made its debut in humans in Wuhan, China. Two months later, the original strain of SARS-CoV-2, called the Wuhan-1 or ancestral strain, was isolated and sequenced. It was now possible to make a vaccine. All the...

read more
A Covid-19 Milestone Attained — A Correlate of Protection for Vaccines

A Covid-19 Milestone Attained — A Correlate of Protection for Vaccines

by Covid Strategies | Dec 10, 2022 | Featured, Science & News, Vaccines

By Peter B. Gilbert, Ph.D., et al. The rapid identification of a correlate of protection (CoP) for Covid-19 vaccines — on the basis of several harmonized randomized phase 3 trials using common validated assays — constitutes an important success in vaccinology. A CoP...

read more
Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB

by Covid Strategies | Dec 7, 2022 | Featured, Science & News

Letter to the Editor from Masaki Imai, D.V.M., Ph.D., et al. Three sublineages of the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have serially transitioned into globally dominant forms — first BA.1, then BA.2, and then...

read more
It Ain’t Over Till It’s Over…but It’s Never Over — Emerging and Reemerging Infectious Diseases

It Ain’t Over Till It’s Over…but It’s Never Over — Emerging and Reemerging Infectious Diseases

by Covid Strategies | Nov 26, 2022 | Featured, Science & News

By Anthony S. Fauci, M.D. As I prepare to step down from my dual positions at the National Institute of Allergy and Infectious Diseases (NIAID), where I have been a physician-scientist for 54 years and the director for 38 years, a bit of reflection is inevitable. As I...

read more
A Bivalent Omicron-Containing Booster Vaccine against Covid-19

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

by Covid Strategies | Oct 17, 2022 | Featured, Science & News, Vaccines

By Spyros Chalkias, M.D., et al. Abstract BACKGROUND The safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214 booster vaccine are not known. METHODS In this ongoing, phase 2–3 study, we compared the 50-μg bivalent vaccine mRNA-1273.214 (25 μg...

read more
Time to Stop Using Ineffective Covid-19 Drugs

Time to Stop Using Ineffective Covid-19 Drugs

by Covid Strategies | Aug 18, 2022 | Featured, Ivermectin, Mainstream Treatment, Repurposed Drugs

By Salim S. Abdool Karim, M.B., Ch.B., Ph.D., and Nikita Devnarain, Ph.D. In practicing evidence-based medicine, physicians use the best evidence currently available on safety and efficacy in making decisions on treatment choices for their patients. During the...

read more
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19

Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19

by Covid Strategies | Aug 18, 2022 | Controversies, Featured, Ivermectin, Mainstream Treatment

By Carolyn T. Bramante, M.D., M.P.H., et al. Abstract BACKGROUND Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an important component of the comprehensive response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic....

read more
Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine

Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine

by Covid Strategies | May 4, 2022 | Featured, Science & News, Vaccines

By Karen J. Hager, M.Sc., et al. Abstract BACKGROUND Coronavirus-like particles (CoVLP) that are produced in plants and display the prefusion spike glycoprotein of the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are combined with an...

read more
Covid-19 Boosters — Where from Here?

Covid-19 Boosters — Where from Here?

by Covid Strategies | Apr 13, 2022 | Featured, Science & News, Vaccines

By Paul A. Offit, M.D. On December 10, 2020, Pfizer presented results from a 36,000-person, two-dose, prospective, placebo-controlled trial of its Covid-19 messenger RNA (mRNA) vaccine, BNT162b2, to the Food and Drug Administration (FDA).1 The vaccine was 95%...

read more
Effect of Early Treatment with Ivermectin among Patients with Covid-19

Effect of Early Treatment with Ivermectin among Patients with Covid-19

by Covid Strategies | Mar 30, 2022 | Controversies, Featured, Ivermectin

By Gilmar Reis, M.D., Ph.D., et al. Abstract BACKGROUND The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19), the disease caused by...

read more
Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections

Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections

by Covid Strategies | Jan 3, 2022 | Science & News

By Laith J Abu-Raddad  Originally Published on November 24, 2021 ~ New England Journal Of Medicine To the Editor: Qatar had a first wave of infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from March through June 2020, after which...

read more
Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections

Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections

by Covid Strategies | Nov 24, 2021 | Commentary

This letter was published on November 24, 2021, at NEJM.org. TO THE EDITOR: Qatar had a first wave of infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from March through June 2020, after which approximately 40% of the population had...

read more

Address:

Commonweal P.O Box 316 | Bolinas, CA 94924

Latest Covid news in your inbox!

Success!

Subscribe

Search Articles

©2021 CovidStrategies/Commonweal | Site maintained by Mercury Multimedia

Privacy Policy | Home